The cost of radiotherapy at an Ontario regional cancer centre: A re- evaluation

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 2, 1999, Pages 87-93

  Earle, Craig ^a   Coyle, Douglas ^a   Smith, Alasdair ^a   Agboola, Olu ^a   Evans, William K ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; CANCER RADIOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HUMAN;

EID: 0032704264     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00026-8     Document Type: Review

References (25)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 1997. Toronto, Canada 1997.
2. Wodinsky H.B., Jenkins R.D. The cost of radiation treatment at an Ontario regional cancer centre. Can. Med. Ass. J. 137:1987;906.
3. Coy P., Schaafsma J., Schofield J.A., Nield J.A. Comparative costs of lung cancer management. Clin. Invest. Med. 17:1994;577.
4. Glazebrook G.A. Radiation therapy: a long term cost benefit analysis in a North American region. Clin. Oncol. 4:1992;302.
5. Green D. The cost of radiotherapy treatments on a linear accelerator. Br. J. Radiol. 56:1983;189.
6. Ball D. Cost implications of different fractionation schedules in palliative radiotherapy. Aust. Health. Rev. 2:1982;24.
7. Smith R.D., Jan S., Shiell A. Efficiency considerations in the expansion of radiation therapy services. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;379.
8. Read G. Estimating the cost of radiotherapy. Clin. Oncol. 6:1994;35.
9. Perez C.A., Kobeissi B., Smith B.D. et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;895.
10. Statistics Canada/Health and Welfare Canada. Radiation therapy workload measurement system. Ministry of supply and Services Canada, 1989.
11. Drummond M.F., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes. 1987;Oxford University Press, Oxford.
12. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C.E. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
13. Evans W.K., Will B.P., Berthelot J.M., Wolfson M.C. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br. J. Cancer. 72:1995;1270.
14. Evans W.K., Will B.P., Berthelot J.M., Wolfson M.C. The cost of managing lung cancer in Canada. Oncology. 9:1995;147.
15. Will B.P., Berthelot J.-M., Houle C., Verma S., Tomiak E., Evans W.K. A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada. Health. Reports. 5:1993;399.
16. Earle C.C., Evans W.K. A comparison of the cost of paclitaxel versus best supportive care in stage IV non-small cell lung cancer. Cancer. Prev. Control. 1:1997;282.
17. Evans W.K. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Sem. Oncol. 23:1996;82.
18. Evans W.K., Chevalier T. The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to standard therapies in stage IV non-small cell lung cancer. Eur. J. Cancer. 32A:1996;2249.
19. Verma S, Will BP, Le Petit C, et al. A Canadian costing model for diagnosis and initial treatment of all stages of breast cancer, 19th Annual San Antonio Breast Cancer Symposium Abstr. 240, 1996.
20. Evans W.K., Will B.P., Berthelot J.-M., Wolfson M.C. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can. J. Oncol. 5:1995;408.
21. Evans W.K., Burpee C., Skinn B. et al. An evaluation of the costs of outpatient chemotherapy administration for small cell lung cancer. Can. J. Oncol. 3:1993;225.
22. Evans W.K., Will B.P., Berthelot J.-M., Earle C.C. The cost of combined modality interventions for stage III non-small cell lung cancer. J. Clin. Oncol. 15:1997;3038.
23. Evans W.K. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health Model lung cancer module. Semin. Oncol. 24 (2 Suppl 7):1997;S7-56.
24. Berthelot J-M, Earle CC, Will BP, Houle C, Evans WK. Sputum dual antibody testing (SDAT) and chemoprevention for lung cancer: a decision analytic model. Proc Am Soc Clin Oncol 1998; 17 (Abstr.2173).
25. Earle CC, Evans WK. The cost-effectiveness of paclitaxel plus cisplatin in advanced non-small cell lung cancer. Br J Cancer 1998.